-
DEPRESCRIBING PREVENTIVE MEDICATIONS IN OLDER ADULTS WITH ADVANCED FRAILTY, DEMENTIA, OR LIMITED LIFE EXPECTANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Feb 25, 2026, 14:42 PM -
PROSPECTIVE EVALUATION OF FRAILTY AND FALL SUSCEPTIBILITY IN GERIATRICS RECEIVING FALL RISK-INCREASING DRUGS AND ITS IMPACT ON QUALITY OF LIFE
Feb 25, 2026, 14:42 PM -
COMPARING METHODOLOGICAL AND REPORTING STANDARDS FOR HEALTH ECONOMIC EVALUATION: INSIGHTS FROM NICE TSD 15, ISPOR GOOD PRACTICES, AND CHEERS 2022 GUIDELINES
Feb 25, 2026, 14:42 PM -
REAL-WORLD EVIDENCE TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT AND PAYER DECISION MAKING: A REVIEW OF POLICY AND GUIDANCE ACROSS EUROPE, CANADA, AND THE UNITED STATES
Feb 25, 2026, 14:42 PM -
SHEDDING LIGHT ON PATIENT-REPORTED OUTCOME MEASURE UTILIZATION ACROSS NSCLC THERAPIES
Feb 25, 2026, 14:42 PM -
GLP-1 RECEPTOR AGONIST-ASSOCIATED THROMBOCYTOPENIA: A NOVEL/EXTENSIVE PHARMACOVIGILANCE EVALUATION FROM SOUTHERN NETWORK ON ADVERSE REACTIONS (SONAR-AI)
Feb 25, 2026, 14:42 PM -
REAL WORLD EVIDENCE FOR LABEL EXPANSION: IDENTIFYING OFF-LABEL USE TRENDS IN THE HOSPITAL SETTING
Feb 25, 2026, 14:42 PM -
SUCCESSFUL USES OF REAL-WORLD EVIDENCE IN FDA LABEL UPDATES: A DESCRIPTIVE ANALYSIS OF REGULATORY TRENDS
Feb 25, 2026, 14:42 PM -
FEASIBILITY ASSESSMENT OF INDIRECT TREATMENT COMPARISON BETWEEN OFF-LABEL RITUXIMAB AND NOVEL TREATMENTS IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF PSILOCYBIN-ASSISTED THERAPY (PAT) FOR PATIENTS WITH TREATMENT-RESISTANT DEPRESSION
Feb 25, 2026, 14:42 PM -
ALIGNMENT OF PATIENT-REPORTED OUTCOME IMPROVEMENTS WITH ICER COST-EFFECTIVENESS AND VALUE-BASED PRICE RECOMMENDATIONS IN RHEUMATOID ARTHRITIS
Feb 25, 2026, 14:42 PM -
THE ANALYTICAL FRAMEWORK OF CLINICAL TRIALS EVALUATING CLINICAL OUTCOMES OF ARTIFICIAL INTELLIGENCE-BASED DIGITAL HEALTH INTERVENTIONS: A SYSTEMATIC LITERATURE REVIEW
Feb 25, 2026, 14:42 PM -
JAV-RARAS: MAPPING THE MULTIDIMENSIONAL BURDEN OF MUCOPOLYSACCHARIDOSIS TYPE IVA (MPS IVA), TYPE VI (MPS VI), AND SPINAL MUSCULAR ATROPHY (SMA) ON PATIENT QUALITY OF LIFE IN BRAZIL
Feb 25, 2026, 14:42 PM -
IMPORTANCE OF ORAL DRUG PRODUCT CHARACTERISTICS TO PATIENTS AND IMPLICATIONS OF CHARACTERISTIC CHANGES FOR MISSED DOSES AND INFORMATION SEEKING
Feb 25, 2026, 14:42 PM -
WHY CURRENT INTERTEMPORAL DISCOUNTING METHODS ARE WRONG, HOW THEY DISTORT HEALTH TECHNOLOGY ASSESSMENT, COST-EFFECTIVENESS ANALYSIS AND ESTIMATES OF THE VALUE OF A LIFE-YEAR AT FULL HEALTH, AND HOW TO FIX THE PROBLEM
Feb 25, 2026, 14:42 PM -
BURDEN OF DISEASE AND PATIENT JOURNEY OF COPD IN BRAZIL: A REAL-WORLD EVIDENCE STUDY USING LINKED PUBLIC DATABASES
Feb 25, 2026, 14:42 PM -
FAERS DATABASE ANALYSIS REVEALS ANENCEPHALY ASSOCIATED WITH ANTIRETROVIRAL DRUG EXPOSURE
Feb 25, 2026, 14:42 PM -
TRENDS IN MORTALITY FROM LIP AND ORAL CAVITY CANCER IN COLOMBIA 2000 - 2024
Feb 25, 2026, 14:42 PM -
DO MULTIPLE PRESENTATIONS AFFECT THE DURATION OF U.S. DRUG SHORTAGES?
Feb 25, 2026, 14:42 PM -
CLINICAL AND ECONOMIC BURDEN IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN THE UNITED STATES
Feb 25, 2026, 14:42 PM
